SSTR2 Inhibitors
5 drugsAbout SSTR2
SSTR2 (somatostatin receptor 2) is a GPCR that inhibits hormone secretion, cell proliferation, and neurotransmission. It is a member of the somatostatin receptor family and regulates diverse physiological processes via downstream signaling pathways.
SSTR2 is a therapeutic target with moderate genetic support, including associations with pneumonitis (score 0.51) and smoking initiation (score 0.51). Strong eQTL/pQTL signals (max H4: 0.99) further support SSTR2's role in disease.
SSTR2 is targeted by 5 FDA-approved small molecule drugs, including SIGNIFOR, LUTATHERA, DETECTNET, PALSONIFY, and NETSPOT, all approved for other indications. Four companies have approved SSTR2-targeting drugs, including RECORDATI RARE and AAA USA INC.
SSTR2 Genetic Evidence Moderate
Genetic evidence provides moderate support for SSTR2 as a drug target.
Further investigation of SSTR2's role in pneumonitis and smoking initiation may reveal novel therapeutic opportunities.
Evidence Across Diseases
4 totalGWAS and other genetic studies link SSTR2 to 4 diseases.
🔗 Colocalization Evidence 3 strong
max H4: 0.99eQTL/pQTL signals for SSTR2 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top SSTR2 Drugs
Four companies have approved SSTR2-targeting drugs.
The presence of established players suggests a moderately competitive market with potential entry barriers.
SSTR2 Drug Modality Landscape
Modalities
Routes of Administration
SSTR2 is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could differentiate new SSTR2-targeting therapies.
SSTR2 Clinical Trials 75 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on SSTR2. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 16 | 9 | 4 | 3 | 69% |
| Phase 2 | 40 | 18 | 14 | 8 | 56% |
| Phase 3 | 12 | 8 | 2 | 2 | 80% |
| Phase 4 | 7 | 4 | 1 | 2 | 80% |
Top Sponsors
By Modality
Top Conditions
SSTR2 Drug Approval Timeline (2012 - 2025)
The first SSTR2-targeting drug was approved in 2012, with the most recent in 2025.
The continued approval of SSTR2-targeting drugs suggests ongoing therapeutic interest and market potential.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 5 companies competing
- • Market share by company
Full Drug Portfolio
- • All 5 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 5-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 48 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on SSTR2. A trial counts if an approved drug acting on SSTR2 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.